Ozempic vs Wegovy: Same Semaglutide, Different Doses and Uses

Ozempic and Wegovy contain the same active ingredient, semaglutide, and are made by the same company, Novo Nordisk. They are not the same product. Ozempic is approved for adults with type 2 diabetes and tops out at 2 mg a week. Wegovy is approved for chronic weight management, for lowering cardiovascular risk in people with heart disease and excess weight, and for the liver disease MASH, and it goes up to 2.4 mg a week, with a 7.2 mg option for some adults. Different labels mean different doses, different pens, different insurance rules and different prices.

If you are wondering whether you can simply use one in place of the other, the short answer is that the molecule is identical but the prescriptions are not interchangeable. Here is how they compare, with prices as of October 2026.

Ozempic vs Wegovy at a glance

	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
First FDA approval	2017	2021
Approved for	Blood sugar control in adults with type 2 diabetes; lowering cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease; lowering the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease	Weight reduction and maintenance in adults with obesity, adults with overweight plus a weight-related condition, and children 12 and older with obesity; lowering cardiovascular risk in adults with established cardiovascular disease and obesity or overweight; noncirrhotic MASH with moderate to advanced liver fibrosis
Weekly injection doses	0.25, 0.5, 1 and 2 mg	0.25, 0.5, 1, 1.7 and 2.4 mg; 7.2 mg (Wegovy HD)
Usual maintenance dose	0.5, 1 or 2 mg	2.4 mg (1.7 mg if needed)
Injection device	Multi-dose pen; you attach a needle and dial the dose	Single-dose pen with a built-in hidden needle; a four-dose FlexTouch pen also exists for 2.4 mg
Tablet version	Ozempic tablets 1.5, 4 and 9 mg daily, for type 2 diabetes	Wegovy tablets, 25 mg daily maintenance, for weight and cardiovascular risk in adults
Approved for teens?	No	Yes, injection, from age 12, for obesity
List price	About $1,028 per pen	About $1,349 per month
Manufacturer self-pay price	$199 to $499 a month by dose	$199 to $399 a month by dose

Is Wegovy the same as Ozempic?

The semaglutide inside is the same molecule. What differs is everything built around it.

• The approved purpose. The FDA reviewed separate trial programs: SUSTAIN for diabetes (Ozempic) and STEP for weight management (Wegovy). Each label reflects only what its trials tested.
• The dose ceiling. Ozempic's maximum is 2 mg. Wegovy's standard maintenance dose is 2.4 mg, and since March 19, 2026 adults who have tolerated 2.4 mg for at least four weeks and need more weight reduction can be moved to 7.2 mg.
• The pen. One Ozempic pen lasts about a month and delivers several doses. Standard Wegovy pens are single-use: four pens in a box, one per week, no needle handling.
• The paperwork. Separate brand names let insurers cover semaglutide for diabetes while restricting or excluding it for weight management.

Eli Lilly's tirzepatide follows the same two-brand pattern; see Mounjaro vs Zepbound.

Dosing schedules compared

Weeks	Ozempic	Wegovy injection
1 to 4	0.25 mg	0.25 mg
5 to 8	0.5 mg	0.5 mg
9 to 12	Stay at 0.5 mg, or 1 mg if more blood sugar control is needed	1 mg
13 to 16	Stay, or 2 mg after at least 4 weeks on 1 mg	1.7 mg
17 onward	0.5, 1 or 2 mg	2.4 mg, or 1.7 mg
Optional	None above 2 mg	7.2 mg after at least 4 weeks on 2.4 mg, adults, for weight reduction

The philosophy differs. With Ozempic, you stop climbing when your blood sugar is where it should be; many people stay at 0.5 mg or 1 mg for years. For kidney protection in type 2 diabetes with chronic kidney disease, the label specifies 1 mg. With Wegovy, the schedule is designed to reach 2.4 mg, the dose with the main weight-loss and cardiovascular evidence, with 1.7 mg as a fallback.

Missed doses. Ozempic: take it within 5 days, otherwise skip. Wegovy: take it if your next scheduled dose is more than 2 days away; if you miss two or more in a row, the label says to restart escalation at a lower dose.

Storage. Both are refrigerated before first use and must never be frozen. An Ozempic pen in use can be kept at room temperature (59°F to 86°F) or in the refrigerator for up to 56 days.

Weight loss: Ozempic vs Wegovy

People do lose weight on Ozempic, and that is where the drug's fame began. But the amounts measured in its trials are smaller than Wegovy's, for two reasons: the doses are lower, and the trials enrolled people with type 2 diabetes, who lose less weight on these drugs than people without it.

Trial	Who	Dose	Length	Average weight change
SUSTAIN FORTE	Type 2 diabetes	Ozempic 1 mg	40 weeks	-6.0 kg (about 13 lb)
SUSTAIN FORTE	Type 2 diabetes	Ozempic 2 mg	40 weeks	-6.9 kg (about 15 lb)
STEP 2 (Wegovy label)	Type 2 diabetes with overweight or obesity	Wegovy 2.4 mg	68 weeks	-9.6%
STEP 1 (Wegovy label)	Overweight or obesity, no diabetes	Wegovy 2.4 mg	68 weeks	-14.9%
STEP UP	Obesity, no diabetes	Wegovy 7.2 mg	72 weeks	-18.7%

In STEP 1, 83.5% of people on Wegovy lost at least 5% of their body weight and 47.9% lost at least 15%, compared with 31.1% and 4.8% on placebo. Ozempic has never been tested in a dedicated weight-management trial in people without diabetes, because that was Wegovy's job.

These are averages over a year or more, with diet and activity counseling alongside the drug. They also describe people who stayed in the trials. When semaglutide 2.4 mg was stopped in the STEP 1 extension, participants regained about two-thirds of the lost weight within a year.

Blood sugar, heart, kidneys and liver

Outcome	Ozempic	Wegovy
A1C in type 2 diabetes	Labeled use. In SUSTAIN FORTE, A1C fell 1.9 points on 1 mg and 2.2 points on 2 mg from a baseline of 8.9%.	Not approved to treat diabetes, though blood sugar falls. People with diabetes on Wegovy are told to monitor glucose.
Heart attack, stroke, cardiovascular death	Approved for adults with type 2 diabetes and established cardiovascular disease (SUSTAIN-6: 6.6% vs 8.9% with placebo).	Approved for adults with established cardiovascular disease and obesity or overweight, with or without diabetes (SELECT: 6.5% vs 8.0% with placebo in 17,604 people without diabetes).
Kidney disease	Approved for adults with type 2 diabetes and chronic kidney disease (FLOW: 24% lower risk of major kidney outcomes).	No kidney indication.
MASH (fatty liver disease with inflammation and fibrosis)	No liver indication.	Accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis in adults, at 2.4 mg.

If you have type 2 diabetes and also want to lose weight, this table is the heart of the decision. Ozempic treats the diabetes with the kidney and cardiovascular labeling behind it. Wegovy delivers a higher dose for weight. Which one is prescribed often comes down to which goal is primary and what your plan will pay for. You cannot take both.

Side effects

Same drug, same side effects, but more of them at Wegovy's higher doses.

Side effect	Ozempic 0.5 mg	Ozempic 1 mg	Wegovy 2.4 mg	Wegovy 7.2 mg
Nausea	15.8%	20.3%	44%	39%
Vomiting	5%	9.2%	24%	22%
Diarrhea	8.5%	8.8%	30%	not in the 7.2 mg table
Constipation	5%	3.1%	24%	20%
Abdominal pain	7.3%	5.7%	20%	12%
Skin tingling or sensitivity (dysesthesia)	not listed	not listed	2%	22%
Hair loss	not listed	not listed	3%	6%

Figures are from the two FDA labels and come from different trials. The 2.4 mg and 7.2 mg columns are from separate studies too, which is why a few 7.2 mg rates look lower than 2.4 mg; in the trial that compared them directly, nausea was 35% on 2.4 mg and 39% on 7.2 mg.

Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents. Neither drug should be used by anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2, or by anyone who has had a serious allergic reaction to semaglutide. Both warn about pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach problems, low blood sugar with insulin or sulfonylureas, worsening of diabetic retinopathy, and aspiration during anesthesia. Wegovy's label adds a warning about an increase in resting heart rate.

Stop the medicine and get urgent care for severe abdominal pain that will not go away, or for swelling of the face or throat or difficulty breathing. Tell your prescriber about vision changes or vomiting and diarrhea that persist. Both labels advise stopping semaglutide at least two months before a planned pregnancy.

The pills: Ozempic tablets and Wegovy tablets

Both brands now exist in tablet form, which adds a second layer to the comparison.

	Ozempic tablets	Wegovy tablets
Approved for	Type 2 diabetes; cardiovascular risk in adults with type 2 diabetes at high risk	Weight reduction and cardiovascular risk reduction in adults
Strengths	1.5 mg, 4 mg, 9 mg	1.5 mg, 4 mg, 9 mg, 25 mg
Schedule	1.5 mg for 30 days, then 4 mg; 9 mg if more control is needed	1.5 mg, 4 mg and 9 mg for 30 days each, then 25 mg
How to take	Once daily on an empty stomach with up to 4 ounces of plain water; wait 30 minutes before food, drink or other oral medicines	Same
Self-pay price	$149 (1.5 mg), $199 (4 mg), $299 (9 mg)	$149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg)

Ozempic tablets reached U.S. pharmacies on May 4, 2026. They are a reformulation of Rybelsus, the original oral semaglutide, in a smaller pill; the two are not interchangeable milligram for milligram (Rybelsus 7 mg corresponds to Ozempic tablets 4 mg, and 14 mg to 9 mg). Wegovy tablets were approved in December 2025; in the OASIS 4 trial, average weight loss at 64 weeks was 13.6% versus 2.2% on placebo. More in GLP-1 pills compared.

Cost and coverage

Prices were checked on NovoCare, Novo Nordisk's patient site, on October 14, 2026.

	Ozempic injection	Wegovy injection
List price	$1,027.51 per pen	About $1,349 per month
Self-pay, introductory	$199 a month for the first two fills of 0.25 or 0.5 mg, new patients, through December 31, 2026	$199 a month for the first two fills of 0.25 or 0.5 mg, new patients, through December 31, 2026
Self-pay, ongoing	$349 a month for 0.25, 0.5 or 1 mg; $499 for 2 mg	$349 a month for 0.25 through 2.4 mg; $399 for 7.2 mg
Commercial insurance that covers it	As little as $25 a month with the savings offer (maximum savings $100 a month)	As little as $25 a month with the savings offer (maximum savings $100 a month)

An oddity worth noticing: at the top of each range, Wegovy 2.4 mg ($349) now costs a cash payer less than Ozempic 2 mg ($499), even though it contains more semaglutide.

• Commercial plans nearly always cover Ozempic for type 2 diabetes, usually with prior authorization confirming the diagnosis. Wegovy coverage for weight management depends on whether the employer bought that benefit; many have not. Wegovy prescribed to reduce cardiovascular risk in someone with established heart disease is sometimes covered where weight management is excluded.
• Medicare Part D covers Ozempic for type 2 diabetes. It may cover Wegovy for cardiovascular risk reduction. For weight management, the Medicare GLP-1 Bridge offers Wegovy injection or tablets at a $50 monthly copay from July 1, 2026 through December 31, 2027 to people who meet its BMI and health criteria; Ozempic is not part of that program. Separately, a Medicare-negotiated price for semaglutide products, reported at $274 for a 30-day supply, is scheduled to take effect January 1, 2027.
• Medicaid programs generally cover Ozempic for type 2 diabetes, often with prior authorization; Wegovy coverage for weight varies by state.

See GLP-1 cost without insurance for every cash-pay route, including tirzepatide.

Can you use Ozempic for weight loss?

Doctors may legally prescribe a drug for a use not on its label, and Ozempic has been widely prescribed off-label for weight loss. Three practical points:

1. Insurance. Plans rarely pay for Ozempic without a type 2 diabetes diagnosis. Prior authorization forms ask for it.
2. Dose. Ozempic stops at 2 mg. The weight-management evidence is for 2.4 mg and above.
3. Price. With Wegovy now at $199 to $349 a month for cash payers, the old argument that Ozempic was the more affordable way to get semaglutide no longer holds.

If weight is the goal and you do not have diabetes, the on-label options are Wegovy, Zepbound and the newer pills. A comparison of all of them is in the best GLP-1 for weight loss.

Switching from Ozempic to Wegovy, or back

The Wegovy label does not give a conversion table from Ozempic, and Ozempic's does not give one from Wegovy. Because the first three dose steps are the same milligram amounts (0.25, 0.5 and 1 mg), prescribers commonly move a patient to the matching or next Wegovy step rather than back to the beginning, provided there has been no break in treatment. Someone stable on Ozempic 1 mg, for instance, might be moved to Wegovy 1 mg or 1.7 mg and then to 2.4 mg after four weeks. That is clinical practice, not a labeled instruction, and your prescriber may choose differently based on side effects and blood sugar.

Points to settle first:

• Do not overlap. Take the first dose of the new brand on the day the old one would have been due.
• Relearn the pen. The devices work differently, and dosing errors happen when people assume otherwise.
• Diabetes medicines. If you take insulin or a sulfonylurea, a higher semaglutide dose can raise the risk of low blood sugar; doses of those drugs may need adjusting.
• Gaps. After two or more missed weekly doses, restarting at a lower dose reduces nausea and vomiting.

The labels do spell out moves between injection and tablet within each brand. A person on Wegovy 2.4 mg can start Wegovy 25 mg tablets one week after the last injection. A person on Ozempic 0.5 mg can start Ozempic tablets 4 mg or 9 mg one week after the last injection. Switching to tirzepatide is a different process, described in switching from Ozempic to Mounjaro.

Which one fits which situation

• Type 2 diabetes, main goal is blood sugar: Ozempic.
• Type 2 diabetes with chronic kidney disease: Ozempic has the kidney indication.
• Obesity or overweight with a related condition, no diabetes: Wegovy.
• Heart disease and excess weight, no diabetes: Wegovy has the cardiovascular indication for this group.
• MASH with fibrosis: Wegovy.
• Age 12 to 17 with obesity: Wegovy injection.
• Type 2 diabetes and obesity together: either may be reasonable; discuss which goal leads and check the formulary.

If semaglutide is not giving you the result you and your prescriber hoped for, the tirzepatide comparisons are the next read: Ozempic vs Mounjaro for diabetes and Wegovy vs Zepbound for weight. One thing to skip: non-prescription GLP-1 patches and supplements do not contain semaglutide, whatever the label implies.